Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20803015 | 0.86 | MAP4K1 (0.36) | ASIC3MAP4K1 | |
| SCHEMBL20803024 | 0.84 | MAP4K1 (0.35) | ASIC3MAP4K1MAP3K5 | |
| SCHEMBL21737827 | 0.81 | MAP4K1 (0.47) | MAP4K1 | |
| SCHEMBL20802605 | 0.80 | MAP3K5 (0.40) | MAP4K1MAP3K5 | |
| SCHEMBL21964139 | 0.78 | MAP4K1 (0.48) | MAP4K1 | |
| SCHEMBL20803415 | 0.78 | ASIC3 (0.38) | ASIC3MAP4K1MAP3K5NOS3 | |
| SCHEMBL23064347 | 0.77 | MAP4K1 (0.37) | ASIC3MAP4K1MAP3K5 | |
| SCHEMBL20802870 | 0.76 | MAP4K1 (0.36) | ASIC3MAP4K1MAP3K5NOS3 | |
| SCHEMBL20802727 | 0.75 | MAP4K1 (0.36) | ASIC3MAP4K1MAP3K5 | |
| SCHEMBL20472682 | 0.75 | TLR8 (0.47) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11168095-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| WO-2019051265-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2018148204-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2018-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283404-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF | DAPK1, ATF1, BAD | ASIC3 4379/4885KDM4E 3408/4885ALDH1A1 3022/4885 |
| US-11034671-B2 | Apoptosis signal-regulating kinase inhibitors and uses thereof | DAPK1, ATF1, BAD | ASIC3 4379/4885KDM4E 3408/4885ALDH1A1 3022/4885 |
| US-11168095-B2 | ASK1 inhibiting agents | MAP3K1, MAP3K10, MAP3K20 | ASIC3 4492/4885KDM4E 2991/4885ALDH1A1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.